Clinical Trials in Sanford, Florida
9 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
End-stage Kidney DiseaseAtherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring2,310 enrolled542 locationsNCT05485961
Recruiting
Phase 2Phase 3
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated466 enrolled318 locationsNCT05312879
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
Hidradenitis Suppurativa
Incyte Corporation550 enrolled101 locationsNCT06959225
Recruiting
Phase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Alopecia Areata
AbbVie1,500 enrolled268 locationsNCT06012240
Recruiting
Phase 1
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Hidradenitis Suppurativa
Incyte Corporation24 enrolled24 locationsNCT07049575
Recruiting
Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Chronic Kidney DiseasesType 2 Diabetes Mellitus
Prokidney685 enrolled95 locationsNCT05099770
Recruiting
Phase 2
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease
AbbVie240 enrolled75 locationsNCT06902558
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Alopecia Areata
Sun Pharmaceutical Industries, Inc.355 enrolled64 locationsNCT07133308
Recruiting
Phase 3
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
COVID-19
BioNTech SE25,500 enrolled208 locationsNCT07300839